Current Illinois CancerCare Clinical Trials

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Study Number: EA9213 (JIT)

Study Summary:
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Status: Open

Study Coordinator(s)
  • Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
  • Hannah, 309-243-3628 hknight@illinoiscancercare.com

Study Link

« Search Again
WordPress PopUp Plugin